Pathways to Prevention (P2P) Program

Daniel H. Solomon, M.D., M.P.H.

Daniel H. Solomon, M.D., M.P.H.

Professor of Medicine
Brigham and Women’s Hospital
Harvard Medical School

Daniel Solomon is a Professor of Medicine and Chief of the Section Clinical Sciences in the Division of Rheumatology at Brigham and Women’s Hospital (BWH). He holds the Matthew H. Liang Distinguished Chair in Arthritis and Population Health at BWH. He has advanced the care and treatment of patients throughout his career, most notably with his investigative research achievements in the epidemiology of rheumatic diseases and the comparative effectiveness of treatments in this area.

Dr. Solomon earned his B.A. and M.D. degrees at Yale University, his M.P.H. at Harvard University, and completed his residency in internal medicine and fellowship in rheumatology at BWH. His early work focused on the safety of NSAIDs and selective COX-2 inhibitors, and he continues to study analgesics. He has also examined osteoporosis prescribing in the United States and conducted several large-scale trials to improve osteoporosis care. His research also has focused on cardiovascular disease in rheumatoid arthritis. He is the Co-Principal Investigator on an NIH-funded trial testing the effect of disease-modifying antirheumatic drugs (DMARDs) on cardiovascular disease.

He has published over 350 articles and has been Principal Investigator on numerous NIH-, foundation-, and industry-supported grants. He currently is Deputy Editor of Arthritis & Rheumatology. As well, he is the Chair of the FDA Arthritis Advisory Committee.

In addition to his investigative achievements, Dr. Solomon has a busy clinical practice and has played a special role in helping the Hispanic community. He has been instrumental in advancing the collaborative clinical Cardiovascular in Rheumatology Medicine practice at BWH. He has mentored more than 30 trainees and junior faculty and was recently awarded The Baughman Faculty Mentoring Award at BWH.

Dr. Solomon disclosed the following conflicts of interest for this workshop:

  • Grant support – PCORI, FNIH and NIH (NIAMS, NHLBI, NIA)
  • Research grants: Amgen, Abbvie, Lilly, Pfizer, Genentech, BMS
  • Epidemiology consultant: Corrona
  • Pfizer, Unpaid Executive Committee PRECISION trial
  • Royalties for chapters on nonsteroidal anti-inflammatory drugs
  • Governance Committee, National Bone Health Alliance
  • FDA, Chair of Arthritis Advisory Committee
  • Arthritis & Rheumatology, Deputy Editor
  • Osteoporosis International, Advisory Editor
  • No personal financial relationship with any pharmaceutical company

Return to the Workshop Agenda

Last updated on